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Abstract
Purpose—To investigate the relationship of changes in ocular blood flow with optic nerve head 
and retinal morphology in open-angle glaucoma patients of African versus European descent over 
four years.
Materials and Methods—In this study, 112 patients with open-angle glaucoma were examined 
at baseline, 79 (59 European descent, 20 African descent) of which were followed for four years. 
Retinal capillary blood flow was assessed with Heidelberg retinal flowmetry. Retrobulbar blood 
flow was measured by color Doppler imaging. Retinal structural changes were examined with 
optical coherence tomography and Heidelberg retinal tomography-III. Mixed-model analysis of 
covariance was used to test for the significance of change from baseline to four-year follow-up, 
and Pearson correlation coefficients were calculated to evaluate linear associations.
Results—In open-angle glaucoma patients of African descent, structural changes of the optic 
nerve head demonstrated a strong association with the end diastolic velocities and resistive indices 
of the short posterior ciliary arteries over four years. In addition, there was a significantly larger 
increase in the avascular area of the inferior retina in patients of African descent, and this 
reduction in retinal capillaries strongly correlated with a reduction in macular thickness.
Conclusion—Reductions in retinal capillary and retrobulbar blood flow strongly correlated with 
changes in the optic nerve head and macular thickness over four years in open-angle glaucoma 
patients of African descent compared to European descent. This data suggests that ocular vascular 
health may be a more influential contributing factor in the pathophysiology of open-angle 
glaucoma in patients of African descent compared to European descent.
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INTRODUCTION
Open-angle glaucoma (OAG) is a leading cause of blindness worldwide, and it 
disproportionately affects persons of African descent (AD) compared to those of European 
descent (ED).1–3 Being of AD is a known risk factor for the development of OAG, and more 
than six times as many people of AD compared with ED develop OAG.1–4 In addition, 
compared with those of ED, OAG patients of AD present at younger ages, experience a 
more severe course of the disease, and undergo a faster rate of progression.5–12 However, 
despite the well-documented disease disparity between persons of AD and ED, the 
underlying mechanisms that explain this disparity remain largely unknown.
Several studies have identified variables that are associated with progressive OAG in patients 
of AD. For instance, those of AD have a statistically significant greater optic disc area, 
deeper maximum cup depth, and thinner corneas compared to those of ED; these parameters 
have been reported to be associated with OAG and its structural progression.11–15 
Additionally, increased levels of oxygen in the anterior chamber have been found in 
individuals of AD, potentially leading to increased oxidative stress and subsequent risk for 
cellular injury.16
Elevated intraocular pressure (IOP) has been identified as a major risk factor for OAG, and 
AD patients often have a higher IOP as compared to those of ED.11,13 Current treatments 
focus on reducing IOP to limit disease progression; however, it is well established that a 
subset of patients continue to progress despite meeting acceptable IOP goals. Furthermore, a 
subset of patients with ocular hypertension do not experience glaucomatous change or 
progression, suggesting that glaucoma progression is multifactorial in etiology and that other 
underlying factors, such as deranged ocular blood flow, may contribute to the pathogenesis 
of the disease.17–18 Compromised vascular perfusion has been shown to be a contributing 
factor for OAG in many individuals.19–20 Both systemic and localized vascular 
abnormalities, such as arterial hypertension, nocturnal hypotension, optic disc hemorrhage, 
migraines, and age-related changes of the vasculature have been linked to OAG.21–23 Several 
large population-based studies have reported an association between decreased ocular 
perfusion pressure with an increase in OAG prevalence, incidence, and progression.21–25 
Furthermore, retinal, choroidal, and retrobulbar blood flow deficiencies have been associated 
with OAG.26–29 However, the exact relationship between deranged ocular blood flow and 
OAG still remains unclear.
Bringing these concepts together, persons of AD experience more systemic vascular 
disorders (e.g., optic disc hemorrhage, peripheral vascular disease, cerebrovascular 
accidents, vascular nephropathy, coronary artery disease) than those of ED.20,25,30–33 Thus, 
since ocular blood flow deficits have been identified as a contributory mechanism for OAG 
progression, it may be the vascular pathology in persons of AD that causes OAG to 
disproportionately affect this patient population.34
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Previously, using retrospective data, we reported that OAG patients of AD had significantly 
lower retrobulbar blood flow velocities compared to those of ED.35 These pilot findings 
were novel but limited by their retrospective and single visit logistics. Herein we present a 
comparative four-year longitudinal analysis describing the relationships between changes in 
retinal and retrobulbar blood flow with alterations in optic nerve head (ONH) and macular 
structure in OAG patients of AD and ED.
MATERIALS AND METHODS
A cohort of patients with OAG were prospectively examined at baseline and every six 
months over four years at the Glaucoma and Diagnostic Center at Indiana University School 
of Medicine. All patients signed an informed consent prior to the initiation of this study, 
which adhered to the tenets of the Declaration of Helsinki. The study protocol was approved 
by the Institutional Review Board committee at the Indiana University School of Medicine.
All participants were required to meet the following inclusion criteria: age 30 years or older 
and best-corrected visual acuity of 20/60 or better in the study eye. In addition, the clinical 
diagnosis of OAG had to be confirmed in the study eye by a fellowship-trained glaucoma 
specialist based upon criteria representative of glaucomatous optic disc or retinal nerve fiber 
layer structural abnormalities and/or automated perimetry visual field changes consistent 
with glaucomatous damage. Patients were excluded for the following reasons: evidence of 
pseudoexfoliation or pigment dispersion, history of acute angle-closure glaucoma or a 
narrow occludable anterior chamber angle, history of inflammatory eye diseases, history of 
intraocular trauma, severe or progressive retinal disease, any abnormality preventing reliable 
applanation tonometry, cataract surgery within the past year, resting pulse < 50 beats per 
minute, or uncontrolled cardiovascular, renal, or pulmonary disease. Participants were 
allowed to continue their preventative blood pressure and cholesterol-lowering medications. 
The data was categorized into groups of AD or ED based on self-reported race. Reporting of 
races other than AD or ED were excluded from this analysis.
One qualified eye was randomly designated as the observational study eye in each subject. 
To limit reproducibility bias with imaging, a single experienced operator with over ten years 
of experience, Brent Siesky (BS), performed all measurements in the same order and at the 
same time of the day for each patient. IOP was measured at each patient visit with 
Goldmann applanation tonometry. Perfusion within the peripapillary retinal capillary beds 
was assessed by confocal scanning laser Doppler flowmetry (CSLDF) (Heidelberg Retinal 
Flowmeter (HRF), Heidelberg Engineering, Heidelberg, Germany). CSLDF provided 
measurements of mean blood flow and blood flow velocity while creating a physical map of 
flow values contained within the retina. CSLDF also differentiated avascular tissue, 
measured as zero flow pixels (no detectable flow), from perfused tissue (presence of flow) 
and, therefore, provided a method for determining the functional capillary density of the 
fundus.36–41 Pixels in poor focus from the rim, large blood vessels, saccades, and areas with 
unsuitable brightness, defined as any DC value <80 or >200, were excluded.39
Peripapillary retinal nerve fiber layer (RNFL) thickness, macular thickness, and optic nerve 
head (ONH) parameters were assessed by optical coherence tomography (OCT) (Stratus 
Siesky et al. Page 3
J Glaucoma. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
software V.4.0, Zeiss Meditec, Dublin, California, USA).42 The examination was performed 
and repeated until good-quality analyses (signal strength < 7) were obtained. Measurements 
were made along a circle concentric with the optic disc (Fast RNFL Thickness acquisition 
protocol) to assess RNFL thickness. The RNFL thickness and cup/disc vertical and 
horizontal ratios were calculated by OCT using the existing software. Topographic analysis 
of the ONH was performed using Heidelberg retinal tomography-III (HRT-III) (Heidelberg 
Engineering, Heidelberg, Germany). The parameters investigated in this study were cup 
area, rim area, cup/disc (C/D) area ratio, RNFL thickness, and linear C/D ratio. The linear 
cup/disc ratio is defined by HRT-III as the average of the cup/disc diameter ratios (square 
root of cup/disc area ratio). The HRT-III was utilized to supplement evaluation of subtle 
RNFL and ONH changes.34,43
Retrobulbar blood flow velocities and vascular resistance were measured with the Philips 
HDI 5000 color Doppler imaging (CDI) system with the microvascular small parts clinical 
option using a 7.5 Mhz linear probe (Philips Ultrasound, Bothell, Washington, USA). Peak 
systolic velocity (PSV) and end diastolic velocity (EDV) were determined for the 
ophthalmic artery (OA), central retinal artery (CRA), nasal posterior ciliary artery (NPCA), 
and temporal posterior ciliary artery (TPCA). The Pourcelot’s resistive index (RI) was 
calculated (RI = (PSV−EDV)/PSV)) for each vessel. Retrobulbar blood flow velocities 
obtained by CDI were standardized by using a printout at each visit to ensure that velocities 
were taken from the same location in each vessel to increase reproducibility and specificity. 
Extensive details on these techniques are found in several previously published 
manuscripts.44–46
Statistical analysis involved performing a mixed-model analysis of covariance (ANCOVA) 
to test for significant change from baseline to four-year follow-up. The models were then 
extrapolated to test for whether the changes varied according to race. Pearson correlation 
coefficients were calculated to evaluate linear associations between changes in blood flow 
and structural progression after four years. Correlations were adjusted for years of 
glaucoma, use of glaucoma or hypertension medications, age 65 or older, body mass index 
category, diabetic status, and sex. Correlations were compared between groups using 
Fisher’s z-tests. P values < 0.05 were considered statistically significant.
RESULTS
In this study, 112 OAG patients were enrolled according to the aforementioned inclusion 
criteria, and 79 patients with comprehensive blood flow and structural assessments were 
followed biannually over a period of four years. For AD participants, 20/29 (69%) 
completed all 8 visits over four years, while 59/83 (71%) ED patients completed all 8 visits 
through four years. Overall baseline characteristics of the populations are presented in Table 
1. At baseline, there were no significant differences between persons of AD and ED with 
respect to IOP, visual field mean deviation, macular thickness, and ONH parameters 
(p>0.05). IOP was also not found to have a statistically significant influence on any measure 
of blood flow over the four-year period for either group (p>0.05). In addition, there was no 
significant difference between AD and ED regarding a history of hypertension, 
hyperlipidemia, cardiovascular disease, family history of cardiovascular disease, smoking 
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status, diabetes, or use of carbonic anhydrase inhibitors, prostaglandin analogues, alpha 
adrenergic agonists, or beta receptor blockers (p>0.05). Use of antihypertensive medications 
(p=0.014) and cholesterol-lowering medications (p=0.030) were more prevalent among 
participants of ED than AD.
Table 2 demonstrates the longitudinal changes in retrobulbar blood flow from baseline to 
four-year follow-up for patients of AD and ED; analysis indicates no significant differences 
throughout the study in retrobulbar blood flow between race groups. As depicted in Table 3, 
comparisons were made between structural measurements with HRT-III and OCT with 
changes in retrobulbar blood flow after four years. Changes in NPCA RI and EDV 
significantly correlated with changes in ONH morphology measured with OCT and HRT-III 
in patients of AD. This relationship was not present in those of ED, indicating a significant 
difference between the groups. In addition, changes in TPCA RI were significantly 
correlated with changes in OCT-measured ONH morphology, and TPCA EDV changes were 
significantly correlated with changes in HRT-III-measured ONH morphology in patients of 
AD, with a significant difference present between races.
Table 4 reports the retinal capillary blood flow of the patients assessed at four-year follow-
up. The number of inferior retinal zero blood flow pixels increased over the four years in 
both AD and ED patients; however, only patients of AD demonstrated a significant increase 
over time (p=0.001). When comparing the changes in the inferior retinal zero flow pixels 
between races, AD patients experienced a significantly larger increase at four years 
(p=0.034). The superior retinal zero blood flow pixels increased in both AD and ED; 
however, only patients of ED displayed a significant increase from baseline to four years 
(p=0.012). No significant difference was observed between races when comparing the 
change in superior retinal zero flow pixels. Additionally, there were no significant 
differences in the superior and inferior retinal mean blood flow between the races.
Table 5 displays the correlations between zero blood flow pixels in patients monitored for 
macular thickness and macular volume changes. In AD patients, changes in the number of 
superior and inferior retinal zero blood flow pixels negatively correlated with macular 
thickness and volume. These correlations were weak in ED patients and did not reach 
statistical significance. These correlation outcomes were significantly different between 
patients of AD when compared to ED. Table 6 demonstrates the baseline and four-year 
changes in optic nerve head structural parameters for persons of AD and ED using OCT and 
HRT-III.
DISCUSSION
The higher rates of OAG and disease progression in persons of AD have been attributed to 
many possible causes, including elevated IOP commonly found within this population.47–49 
However, other studies have found no differences in IOP based on racial differences, 
suggesting that IOP-independent factors may contribute to the disproportionate 
glaucomatous changes in persons of AD.5–12 Importantly, persons of AD are also known to 
have increased rates of systemic vascular diseases, such as hypertension and cardiovascular 
disease.30–33 Results from the Ocular Hypertension Treatment Study suggest that these 
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increased rates of cardiovascular disease in AD persons may be linked to increased rates of 
glaucoma.50
Previously, we demonstrated, through a retrospective analysis, that patients of AD had a 
significantly lower retrobulbar blood flow in all vascular territories, supporting the 
hypothesis that vascular abnormalities may contribute to the pathogenesis of glaucoma 
differently in patients of AD.35 Other studies have found decreased systemic and ocular 
blood flow to be correlated with glaucomatous structural damage in the retina and 
ONH.51–53 This current four-year prospective analysis was designed to examine how 
changes over time in retrobulbar and retinal capillary blood flow relates to glaucomatous 
ONH and retinal structural changes in patients of AD compared to ED.
In this cohort of patients, changes during four years in both the EDV and the RI of the short 
posterior ciliary arteries, which feed the ONH, strongly correlated to morphological changes 
in ONH structure in patients of AD only. Many previous studies have found retrobulbar 
blood flow variables to be linked to glaucomatous damage. For instance, Calvo et al. 
reported that OA EDV and mean velocities were reduced in subjects who converted to 
glaucoma based on Moorfields Regression Analysis.54 Jimenez-Aragon et al. found that the 
EDV and RI of the OA and CRA were significantly different between subjects who 
structurally progressed compared to those who did not progress.55 Zeitz et al. showed that 
the EDV and PSV of the short posterior ciliary arteries were decreased in subjects who 
structurally progressed.56 All of these reported findings support the concept of a potential 
retrobulbar blood flow influence on structural glaucomatous disease progression. Our study 
suggests that blood flow, specifically in the short posterior ciliary arteries, may be a 
contributory mechanism to structural glaucomatous changes of the ONH in patients of AD.
In our study population, we also found that inferior temporal retinal capillary density was 
significantly reduced in patients of AD compared to ED over a four-year period. As part of a 
comprehensive analysis of structural changes, we found this retinal capillary dropout to be 
strongly correlated with macular thinning in patients of AD. This finding is important in the 
realm of OAG because the macular inner retinal layer thickness has been reported to be 
useful for early detection and progression monitoring in glaucoma.57 Our results parallel 
previous findings that suggest retinal blood flow is related to structural changes. For 
instance, ONH morphology changes in primary OAG patients and OAG patients of AD 
strongly correlate with retinal blood flow changes.51,53 A previous study by Resch et al. 
found that reduced retinal blood flow was strongly correlated with ONH damage and visual 
field loss in OAG patients.52 Our new data indicates that loss of retinal capillaries over time 
is another vascular contributory biomarker and newly identified mechanism that may 
account in part for the disproportionate glaucomatous progression observed in OAG patients 
of AD.
In this cohort of patients, there was no baseline difference between the two groups with 
respect to IOP, visual field mean deviation, or HRT-III and OCT structural changes, thereby, 
indicating that the differences between study groups observed over the four years were likely 
not related to IOP or disease severity differences present at baseline. However, we recognize 
that our study is not without limitations. One limitation of our study was that race was self-
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reported. This may have affected the populations into which the participants were separated; 
however, prior research has shown that self-reported race strongly correlates with more 
technical measures of racial classification that utilize genetic information.58 A second 
limitation is the larger number of ED than AD patients, which could potentially limit the 
scope of comparisons between groups. However, all available data from the cohorts were 
included without selection bias. In addition, the four-year follow-up with repeating 
measurements every six months by the same observer (BS) adds strength to the analysis. 
Furthermore, while our study demonstrates a correlation between changes in ocular blood 
flow with ONH and macular structure changes in AD patients with OAG, it was not 
designed to establish causation. Finally, our study lacked control groups of healthy persons 
without evidence of OAG.
Persons of AD experience a disproportionate rate of OAG disease and progression. While 
many factors likely play a role in this disparity, our data shows that over a multi-year 
timeframe ONH and retinal structural changes strongly correlate with changes in retrobulbar 
and retinal blood flow in OAG patients of AD. This suggests that ocular blood flow may be 
a stronger contributing factor in the pathophysiology of OAG in AD patients compared to 
patients of ED. The differing influence of the observed blood flow changes over time on 
glaucomatous disease progression between groups may be due to persons of AD having 
compromised vascular autoregulation in tissues around and within the optic nerve compared 
to their ED counterparts. Although our study has established differences over time in the 
ocular vasculature in patients of AD and ED, and its possible contribution to glaucomatous 
structural progression, the physiological and/or pathological mechanisms behind these 
vascular differences remain unknown.
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Table 1
Baseline demographics and glaucoma medications for open-angle glaucoma patients of African and European 
descent
African Descent European Descent
Total participants 29 83
Average Age (SD) 63 (±11) 65 (±11)
Age ≥ 65 15 47
Male 8 36
Non-insulin dependent diabetes mellitus 4 17
BMI ≥ 25 24 50
Hypertension medication use 13 38
Intraocular Pressure (SD) 16.9 (±3.8) 15.9 (±4.5)
Glaucoma medications*
  Carbonic anhydrase inhibitors (e.g. Dorzolamide) 8 11
  Prostaglandin analogues (e.g. Latanoprost) 15 53
  α adrenergic agonist (e.g. Brimonidine) 8 13
  Beta receptor blockers (e.g. Timolol) 13 21
*
Patients may be using more than one glaucoma medication
Note: There was no significant difference between AD and ED patients regarding a history of hypertension, hyperlipidemia, cardiovascular disease, 
family history of cardiovascular disease, smoking status, diabetes, or use of carbonic anhydrase inhibitors, prostaglandin analogues, α adrenergic 
agonist, or beta receptor blockers (p>0.05).
Table 1 legend: SD-standard deviation; BMI-body mass index
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